Discovery Life Sciences and Mindpeak partnered to streamline clinical trial biomarker workflows using AI-assisted tissue analysis. The collaboration is designed to reduce variability in whole-slide interpretation between pathologists by combining Mindpeak’s AI pathology workflow and microdissection tools with Discovery’s flow cytometry and histopathology services. The companies said the effort aims to improve biomarker quantification reproducibility across immunohistochemistry and multiplex immunofluorescence workflows. Discovery added peer-to-peer pathologist training to its capabilities, positioning the partnership to focus both on automation and standardization. The firms plan to present use cases at the American Association for Cancer Research annual meeting in San Diego next month, signaling an intent to translate the integration into sponsor-ready trial outputs rather than solely internal R&D efficiencies.